← Back to Search
Recommendations For Adjunctive Basic Skin Care In Patients With Psoriasis
T. Luger, S. Seité, P. Humbert, J. Krutmann, R. Triller, B. Dréno
Published 2014 · Medicine
Download PDFAnalyze on Scholarcy
BackgroundPsoriasis is a multifactorial disease involving both genetic predisposition and external triggers, resulting in epidermal and immune dysfunctions. Regardless of the severity of the disease, patients require additional basic topical treatment with emollients. Basic skin care products are well known for their role in moisture retention and symptom control in psoriasis, yet patients underuse them. Dry skin and cutaneous inflammation are associated with an impaired epidermal barrier function. This breakdown of the skin barrier causes the release of proinflammatory mediators that exaggerate inflammation.Objectivesto provide recommendations for the use of emollients (including ceramides, urea, keratolytic agents, zinc salts, niacinamide), thermal water and skin care products in psoriasis.MethodsA review of the current literature from 2000 to 2012 using Medline and Ovid was performed by a working group of five European Dermatologists with clinical and research experience in psoriasis.ResultsEither alone or used adjunctively, basic topical therapy can restore and protect skin barrier function, increase remission times between flare-ups and enhance the effects of pharmaceutical therapy.ConclusionWe provide physicians with a tool to assist them in implementing basic skin care in an integrated disease management approach.
This paper references
Abnormality of water barrier function in psoriasis. Role of ceramide fractions.
S. Motta (1994)
Molecular dissection of psoriasis: integrating genetics and biology.
James T. Elder (2010)
Ceramides and Skin Function
L. Coderch (2003)
Psychologic factors in psoriasis: consequences, mechanisms, and interventions.
D. Fortune (2005)
An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid.
E. Tanghetti (2000)
Water-in-oil emollients as steroid-sparing adjunctive therapy in the treatment of psoriasis.
K. Watsky (1992)
The use of hydroxy acids on the skin: characteristics of C8‐lipohydroxy acid
D. Saint-Léger (2007)
Current severe psoriasis and the Rule of Tens
A. Finlay (2005)
How patients experience psoriasis: results from a European survey
S. Fouéré (2005)
An Inverse Relationship Between Ceramide Synthesis and Clinical Severity in Patients with Psoriasis
Yunhi Cho (2004)
Ceramides and Cell Signaling Molecules in Psoriatic Epidermis: Reduced Levels of Ceramides, PKC-α, and JNK
B. Lew (2006)
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
A. Gottlieb (2008)
The management of dry skin with topical emollients – recent perspectives
E. Proksch (2005)
Psoriasis Mechanisms of Disease
FO Nestle (2009)
In touch with psoriasis: topical treatments and current guidelines
G. Murphy (2011)
[Salicylic acid and urea--possible modification of the keratolytic effect of salicylic acid by urea].
B. Gabard (1989)
Moisturizing cream ameliorates dryness and desquamation in participants not receiving topical psoriasis treatment.
Z. Draelos (2008)
Therapeutic Moisturizers as Adjuvant Therapy for Psoriasis Patients
C. Gelmetti (2009)
Interaction of mineral salts with the skin: a literature survey
T. Polefka (2012)
Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis
R. Cid (2009)
Streptococcus sp. and Staphylococcus aureus isolates from patients with psoriasis possess genes that code for toxins (superantigens): clinical and therapeutic implications.
Jessica El Ferezli (2008)
Mechanisms of Disease: Psoriasis.
Frank O. Nestle (2009)
Treatment of localized psoriasis with a topical formulation of zinc pyrithione.
G. Sadeghian (2011)
Depression and Quality of Life in Psoriasis
A. Voorhees (2009)
Emollients, moisturizers, and keratolytic agents in psoriasis.
J. Fluhr (2008)
The role of salicylic acid in the treatment of psoriasis
M. Lebwohl (1999)
Double‐blind clinical study reveals synergistic action between alpha‐hydroxy acid and betamethasone lotions towards topical treatment of scalp psoriasis
K. Kostarelos (2000)
Genome - wide scan reveals associ - tion of psoriasis with IL - 23 and NF - kappa pathways
Adjuvant role of a new emollient cream in patients with palmar and/or plantar psoriasis: a pilot randomized open-label study.
N. Cassano (2010)
Modulation of Interleukin‐8 and staphylococcal flora by Avène hydrotherapy in patients suffering from chronic inflammatory dermatoses
C. Casas (2011)
Psoriasis: New insight about pathogenesis, role of barrier organ integrity, NLR / CATERPILLER family genes and microbial flora
C. Mattozzi (2012)
Salicylic Acid 6% in an ammonium lactate emollient foam vehicle in the treatment of mild-to-moderate scalp psoriasis.
L. Kircik (2011)
Treatments for psoriasis and the risk of malignancy.
Rita V. Patel (2009)
The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder
S. Philipp (2006)
Streptococcus sp. and Staphylococcus aureus Isolates from Patients with Psoriasis Possess Genes That Code for Toxins (Superantigens): Clinical and Therapeutic Implications
Jessica El Ferezli (2008)
Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation.
Y. Bae (2012)
Adherence to topical treatment in psoriasis: a systematic literature review
S. Devaux (2012)
Urea uptake enhances barrier function and antimicrobial defense in humans by regulating epidermal gene expression
S. Grether-Beck (2012)
Aduvant role of a new emollient cream in patients with palmar and / or plantar psoriasis : a pilot randomized open - label study
ZD Draelos (2010)
The effects of Detergents on Hydration and Skin Surface EJD , vol . 24 , n ◦ 2 , March - April
P Thune (2014)
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies.
A. Menter (2009)
German S3-guidelines on the treatment of psoriasis vulgaris (short version)
A. Nast (2012)
Exploring the association between cardiovascular and other disease‐related risk factors in the psoriasis population: the need for increased understanding across the medical community
A. Menter (2010)
Recommendation: Daily sun protection in the prevention of chronic UV‐induced skin damage
P. Elsner (2007)
Current and future management of psoriasis
A. Menter (2007)
Adopted guidelines of care for the topical management of psoriasis from American and German guidelines
A. Raddadi (2011)
[Recovery rate of externally administered glucocorticoids on the skin surface].
W. Wohlrab (1986)
Emollient for maintenance therapy after topical corticotherapy in mild psoriasis
S. Seité (2009)
Nicotinamide is a potent inhibitor of proinflammatory cytokines
J. Ungerstedt (2003)
Psoriasis: an epidemiological evaluation of disease burden in 590 patients
N. Meyer (2010)
Role of Ceramides in Barrier Function of Healthy and Diseased Skin
M. J. Choi (2005)
Ceramide analogue 14S24 selectively recovers perturbed human skin barrier
K. Vávrová (2007)
Current and future management of psoiasis
A Menter (2007)
The effects of detergents on hydration and skin surface lipids.
P. Thune (1996)
Nicotinamide: a potential addition to the anti‐psoriatic weaponry
M. Namazi (2003)
Impaired skin barrier function in dermatologic disease and repair with moisturization.
M. Lebwohl (2005)
Impact of Avène hydrotherapy on the quality of life of atopic and psoriatic patients
C. Taieb (2011)
Pilot, multicenter, double-blind, randomized placebo-controlled bilateral comparative study of a combination of calcipotriene and nicotinamide for the treatment of psoriasis.
D. Levine (2010)
Staphylococcal toxins in patients with psoriasis, atopic dermatitis, and erythroderma, and in healthy control subjects.
N. S. Tomi (2005)
Salizylsäure und Harnstoff — mögliche Beeinflussung der keratolytischen Wirkung von Salizylsäure durch Harnstoff
B. Gabard (1989)
Psoriasis − epidemiology and clinical spectrum
E. Christophers (2001)
Psoriasis and cardiovascular risk factors: a case-control study on inpatients comparing psoriasis to dermatitis.
J. Shapiro (2012)
P. Moreau (2007)
Clinical efficacy of Avène hydrotherapy measured in a large cohort of more than 10,000 atopic or psoriatic patients
C. Mérial-Kieny (2011)
The concept of psoriasis as a systemic inflammation: implications for disease management
K. Reich (2012)
Role of Topical Emollients and Moisturizers in the Treatment of Dry Skin Barrier Disorders
M. Lodén (2003)
Genomewide Scan Reveals Association of Psoriasis with IL-23 and NF-κB Pathways
R. Nair (2009)
This paper is referenced by
Tolerance and efficacy of a new celastrol-containing balm as adjunct care in psoriasis.
M. Thouvenin (2020)
Salvianolic Acid B in Microemulsion Formulation Provided Sufficient Hydration for Dry Skin and Ameliorated the Severity of Imiquimod-induced Psoriasis-like Dermatitis in Mice
Jiun-Wen Guo (2020)
Efficacy and tolerance assessment of a new type of dermocosmetic in infants and children with moderate atopic dermatitis
F. Gayraud (2015)
Primjena suvremenih topikalnih pripravaka u liječenju psorijaze
I. Petric (2017)
Evaluation of cutaneous surface parameters in psoriatic patients
S. Cannavó (2017)
A Real-World, Non-interventional Indian Study Evaluating Intensive Plant-Based Butter Moisturizing Cream in Psoriasis
H. Jerajani (2019)
In vitro models of psoriasis
B. Roy (2018)
Understanding effects of topical ingredients on electrical measurement of skin hydration
J. Crowther (2016)
Adjuvant treatment of chronic plaque psoriasis in adults by a herbal combination: Open German trial and review of the literature
U. Wollina (2018)
Imiquimod‐induced psoriasis‐like inflammation in differentiated Human keratinocytes: Its evaluation using curcumin
Sandeep R. Varma (2017)
Stellenwert der Basistherapie bei Psoriasis Importance of basic therapy in psoriasis
Diamant Thąci (2015)
4'-O-β-D-glucosyl-5-O-methylvisamminol ameliorates imiquimod-induced psoriasis-like dermatitis and inhibits inflammatory cytokines production by suppressing the NF-κB and MAPK signaling pathways
J. Fu (2020)
Skin Care Products for Healthy and Diseased Skin.
C. Surber (2018)
Stellenwert der Basistherapie bei Psoriasis
D. Thąci (2015)
Corticosteroid Cream Once Daily plus an Emollient Cream in comparison with Corticosteroid Cream Twice Daily in Plaque Psoriasis: An Intra- Patient, Randomized Assessor-Blinded, Ultrasound Evaluation Study
Francesco Lacarrubba (2014)
Importance of basic therapy in psoriasis
D. Thąci (2015)
DFD-01 Reduces Transepidermal Water Loss and Improves Skin Hydration and Flexibility
J. M. Jackson (2017)
A cosmeceutical formulation based on boswellic acids for the treatment of erythematous eczema and psoriasis
S. Togni (2014)
Aquaporin-3 expression in common hyperproliferative skin disorders: an immunohistochemical study
Wafaa M. Ramadan (2017)
Novel psoriasis therapies and patient outcomes, part 1: topical medications.
M. A. Feely (2015)